Courts reverse ruling in Teva-Galderma patent case

Jan. 31, 2020

The U.S. Court of Appeals for the Federal Circuit has reversed the district court’s judgment on a patent infringement case brought against Teva by dermatological company Galderma.

Galderma, formerly a subsidiary of L'Oreal and then of Nestlé, filed suit after Teva submitted an Abbreviated New Drug Application in December 2016, seeking approval to market a generic version of anti-rosacea cream Soolantra.

The U.S. District Court for the District of Delaware ruled against Galderma in June 2019. Galderma appealed, while Teva launched its generic drug product.

Yesterday, the Federal Circuit concluded that the previous judge had erred in finding that three Galderma patents on Soolantra were invalid — handing a big win to the dermatology company.The three patents, which all expire in 2034, relate to methods of treating inflammatory lesions caused by rosacea, a chronic skin condition that affects millions of people and has no cure.

Read the court decision